Ariosa Diagnostics, which provides genetic tests that determine fetal conditions and characteristics for expectant mothers, removed the terms of its IPO in an amendment filed with the SEC on Tuesday. The San Jose, CA-based company had originally announced its IPO terms last week; it planned to raise $60 million by offering 3.5 million shares at a price range of $16 to $18, implying a fully diluted market value of $323 million (at the midpoint).
Ariosa Diagnostics, which was founded in 2008 and booked $63 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol AROS. The company initially filed confidentially on December 19, 2013. J.P. Morgan and Citi are the joint bookrunners on the deal.
